Monoclonal and polyclonal antibodies with known specificity for either the 54K envelope glycoprotein or the 48K non-structural glycoprotein of yellow fever (YF) virus-infected cells were studied in plaque reduction neutralization tests. Viruses employed in the tests comprised wild-type and vaccine strains of YF and a selection of other flaviviruses. Of 17 monoclonal antibodies examined, six of the 54K-specific antibodies neutralized at least one YF preparation. Both vaccine and wild-type YF viruses varied in their susceptibility to neutralization and there were also differences between individual 17D vaccine strains. The monoclonal antibodies produced a range of titres with the different viruses, the most potent, 864, leaving no non-neutralizable fraction. Addition of anti-globulin, complement or other antibodies did not affect the results. YF-neutralizing antibodies which bound to other flaviviruses did not necessarily neutralize them; hence, neutralization could be defined as either homotypic, heterotypic or both homotypic and heterotypic. A polyclonal antiserum and a broadly reacting monoclonal antibody produced almost identical neutralization results in tests with wild-type YF viruses. In contrast, the polyclonal antiserum produced higher titres with vaccine strains of YF. In mouse passive protection experiments on the other hand, the monoclonal antibody did not differentiate between these viruses.
INTRODUCTION
Until recently, the flaviviruses were placed in the family Togaviridae (Fenner et al., 1974) but they are now classified in the family Flaviviridae (Brown, 1985) . The genus Flavivirus, of which yellow fever (YF) virus is the type species (Wildy, 1971) , currently comprises some 65 antigenically distinct viruses subdivided (Madrid & Porterfield, 1974) largely on the basis of cross-reactivity in plaque reduction neutralization tests performed with varying antibody and constant virus concentrations. They were subsequently arranged into seven subgroups or complexes by taking into account the invertebrate vector and the antigenic relationships as determined by haemagglutination inhibition (HAl) and complement fixation tests (Porterfield, 1980) . The precise mechanisms of flavivirus neutralization have not been defined although it is known that the viral envelope glycoprotein is responsible for eliciting a neutralizing antibody response (Shapiro et al., 1971 ; Kitano et al., 1974; Heinz et al., 1981 ; Monath et al., 1984; Gould et al., 1985) .
With the advent of monoclonal antibodies (MAb) (KShler & Milstein, 1975) it is now possible to examine the antigenic interrelationships of the flaviviruses under closely defined conditions and to probe the mechanisms of neutralization. Previously, we described the antigenic crossreactions between flaviviruses and MAb prepared against YF virus using immunofluorescence microscopy (Gould et al., 1985) . In this paper, we present the results of YF virus and flavivirus neutralization studies using the same monoclonal and polyclonal antibodies. (Liprandi, 1981) Asibi YI (Fitzgeorge & Bradish, 1980) Wild YF monkey serum (10/4/68); R. Fitzgeorge, Porton Down Wild YF (Fitzgeorge & Bradish, 1980) Wild YF monkey serum 10/1/75; Trinidad Wild YF (Varma et al., 1975/76) B1 wild YF monkey serum 1973; Brazil B2,3,6,7,9,10,12,14,15,16, wild YF human serum 1978 Brazil B4,5,8,11,13, wild YF Haemagogus sp. 1973 ; Brazil for individual MAb although they were reproducible for any individual virus; the most potent neutralizing MAbs were equally as or more effective than high titre polyclonal antisera. Heterotypic neutralization was also observed when other flaviviruses were included in the tests. Our results illustrate some of the problems that can arise if the neutralization test is used for classification of the flaviviruses. Moreover, they demonstrate that effective neutralization of YF virus infectivity depends upon both the presence and the appropriate presentation of a 'critical epitope' in the viral envelope glycoprotein.
METHODS

Viruses.
A selection of ftaviviruses from each of the seven recognized subgroups and also vaccine and wild-type substrains of YF virus were used. The designations and sources are shown in Table 1 . Each virus pool was stored at -70 °C as a 20% infected suckling mouse brain suspension.
Cells and media. Vero cells were grown in Leibovitz L15 medium containing 5~ foetal calf serum (FCS), 10~ tryptose phosphate broth, penicillin (100 units/ml) and streptomycin (100 ~tg/ml). For maintenance medium the concentration of FCS was reduced to 2~.
Selection oJ]olaque variants. Appropriate dilutions of virus in maintenance medium were added to monolayers of Vero cells in 5 cm Petri dishes (1 ml/dish). After incubation for 1 h at 37 °C the inoculum was removed, the monolayers washed three times with maintenance medium and 6 ml maintenance medium containing 0.5~ Seakem agarose (FMC Corporation, Rockland, Me., U.S.A.) was added to each dish. After incubation for 7 days, well-separated plaques were removed as a plug ofagarose using a Pasteur pipette. Each plaque was placed in 1 ml growth medium and frozen at -70 °C. The viruses were considered to have been satisfactorily plaque-purified when this procedure had been repeated three times. Infected suckling mouse brain pools of these virus variants selected on the basis of size were prepared before use. Large plaques had a diameter of at least 3 mm and small plaques had a diameter of not more than 1 mm.
Plaque reduction neutralization tests. Two methods were employed. In the first, constant antibody and varying virus dilutions were used to produce a serum neutralization index (SNI) for each antibody as described by Bradish et al. (1962) . The virus to be tested was diluted in tenfold steps using maintenance medium and then 0.04 ml aliquots were dispensed into microtitre plates to occupy 12 wells per dilution. An equal volume of antibody at a dilution of 1/20 in maintenance medium was added to each well and the mixtures were incubated at 37 °C for 1 h. Vero cells diluted in maintenance medium were added to each well (40000 cells/well) and the mixtures incubated at 37 °C for 3 h. Maintenance medium containing 1.5~ CM-cellulose was then added and the plates were incubated at 37 °C until plaques were produced (7 to 14 days). The monolayers were fixed with 10~ formalin in saline and stained with naphthalene black. The SNI is the reduction in virus infectivity, expressed as loglo, when compared with a control non-related antibody. Attempts to mediate (Chanas et al., 1982) 1 1 1 1 1 1 1 2 2 3 2 2 2 2 1 2 1 2 2 2 2 1 1 1 2 1 2 843 1 1 1 1 2 1 3 1 2 2 2 1 2 2 2 2 1 1 1 1 2 612 1 1 I 1 1 1 1 1 1 2 2 3 3 3 1 2 2 1 3 1 3 3 2 1 1 1 2 2 2 RHI 4 2 3 3 4 3 2 3 3 1 2 2 2 3 2 3 1 2 1 2 2 1 2 2 3 2 1 1 1 3 2 2 RH2 1 1 1 2 1 1 1 1 2 2 3 1 2 1 2 1 1 3 1 2 2 1 1 1 3 2 2 * Antibody titres expressed as log~0 reduction of virus titre.
Yellow fever virus neutral&ation 2525 In the second method, neutralization tests (N) were performed with both varying virus and varying antibody dilutions in chequerboard fashion. When this was required, serial tenfold dilutions were inoculated into microtitre plates and serial dilutions of antibody were added. The procedure then followed that described above. The highest dilution of antibody that produced 50~ reduction of plaque numbers is the antibody titre. When it was required virus preparations were sonicated for 60 s at 4 °C (50 W, Dawe Soniprobe) and filtered through a Sartorius membrane (220 nm pore size) to remove aggregates.
Hyperimmune antisera. Two rabbit antisera RH 1 and RH2 prepared against purified YF (W 17D) vaccine and West Nile (WN) viruses respectively were used. In indirect immunofluorescence tests they had been shown previously to react with all the viruses used in this paper. These antisera were also shown to react with the 54K envelope glycoprotein of YF virus (Gould et al., 1985) .
Hyperimmune mouse antisera against BI2 wild-type and W 17D YF viruses were prepared by intraperitoneal inoculation of infectious virus followed at weeks 2, 3 and 4 by intradermal inoculation. The antisera were collected during the fifth week.
Monoclonal antibodies. These were prepared against either the YF 17D vaccine (United Kingdom substrain W17D), or the French neurotropic vaccine (FNV) virus as described previously (Gould et al., 1985) .
Mouse protection experiments. Two methods were employed. In the first, which utilized the principle of virus neutralization, serial dilutions of virus were mixed with equal volumes of MAb 612 diluted 1/20. The mixtures were held for 60 min at 37 °C and then inoculated intracerebrally (0.1 ml) into groups of 3-to 4-week-old randomly bred female mice (strain TO, Tuck & Sons, Battlesbridge, Essex, U.K.). In the second procedure (passive antibody transfer) the mice were inoculated intraperitoneally with 0.1 ml MAb 612 (as ascitic fluid) and then 24 h later groups of these mice were challenged intracerebrally with appropriate dilutions of virus. The mice were examined daily for up to 20 days.
RESULTS
Neutralization using MAb and YF viruses
Neutralization tests were carried out with constant antibody and varying virus dilutions (SNI) using MAb prepared against YF virus. Eight 54K-and nine 48K-specific antibodies were tested. In the first series of experiments a selection of YF vaccine and wild-type viruses was used. It is important to remember that except for MAb 864, which is uniquely specific for all 17D vaccines, all the other antibodies have been shown to react to similar titres with all the YF viruses when tested by indirect immunofluorescence (Gould et al., 1985) . The results of" SNI tests (Table 2) are presented only for the antibodies that produced neutralization. Six of the eight 54K-specific and none of" the 48K-specific antibodies were positive. However, the antibodies that produced neutralization did not neutralize all YF viruses. MAb 864 neutralized all 17D
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A. BUCKLEY AND E. A. GOULD were neutralized effectively by several of the antibodies whereas others were poorly neutralized by most of the antibodies. The wild-type isolates from South America were originally from humans, monkeys or mosquitoes. No correlation was found between their source and ability to be neutralized. Also shown in Table 2 are the results with two hyperimmune rabbit antisera RH1 and RH2 prepared against YF (W 17D) and WN viruses respectively. Both antisera neutralized many but not all the YF viruses; however, overall the performance of the most broadly reactive monoclonal antibody (MAb 612) was equal to that of the hyperimmune antisera. YF viruses that were neutralized effectively by monoclonal antibodies were similarly neutralized by the hyperimmune antisera. The same held true for the poorly neutralized YF viruses. The relative potencies of RH1 and RH2 were similar when tested with wild-type YF viruses but differed with the 17D vaccine against which RH1 was prepared.
We then attempted to mediate or potentiate neutralization in separate experiments by the addition of either mouse anti-globulin or guinea-pig complement to the virus antibody mixtures. The results obtained, however, were essentially the same as those presented above. We also combined two or three antibodies to see whether or not this made any difference to the results. For these tests, YF 17D (P17D) was used. The results were essentially similar to those of individual antibodies, i.e. if MAb 864 was present in the combination a high titre was observed and in all other cases the neutralization index corresponded to the titres obtained with the individual monoclonal antibodies.
SNI titrations were also carried out using plaque-purified derivatives of vaccine and wild-type YF viruses to compare their abilities to be neutralized with the parent viruses from which they 
2527
were derived. These results are presented in Table 3 . In general, plaque variants from 17D vaccines were neutralized no more effectively than the parent viruses, whereas with the Asibi virus plaque-purified derivatives, most were neutralized by more monoclonal antibodies than the parent virus although one (ASsp3) produced results almost identical to parent virus. With plaque-purified viruses derived from wild-type B5 virus on the other hand, the number of antibodies that neutralized each plaque-purified virus was as for the parent strain but the antibody titres were higher in neutralization tests with the plaque-purified viruses. As was shown previously MAb 864 was highly effective at neutralizing 17D viruses but two 17D smallplaque variants (W 17Dsp), selected because they do not possess the 864 epitope (E. A. Gould, unpublished data), were not neutralized by MAb 864. Virus neutralization was then studied in more detail using MAb 612 and polyclonal antibody RH1. For these experiments antibody and virus suspensions were diluted and mixed in a chequerboard type of titration. The results of these neutralization tests with wild-type YF viruses are presented in Fig. 1 (a) . There was no clear-cut difference between the two antibodies, which both showed either high, low or no neutralizing activity when tested with the same virus strains. On the other hand, the neutralizing activity of MAb 612 relative to RH1 varied from slightly superior to slightly inferior with the different viruses that could be neutralized. When these results were compared with those obtained in SNI titrations there was not always a direct relationship between titres obtained by the two methods. For example, the SNI titres of B 13 and B8 viruses were 1 and 3 respectively but they could not be distinguished in N tests (Fig. 1 a) . This applied to both the monoclonal and the polyclonal antibodies.
The results of N tests with all YF vaccines are presented in Fig. 1 (b) . All vaccine preparations from all countries were titrated; however, since they were similar only one of each type of vaccine is shown. These results contrast with those seen for the wild-type viruses since with all the vaccines (i.e. 17D, 17DD and FNV) MAb 612 had a much lower titre than was seen with wild-type viruses (refer to Fig. 1 a) and also consistently showed lower potency than RH1 (Fig.  1 b) . In order to eliminate the possibility that virus aggregation might account for the relatively poor neutralization activity of MAb 612 with vaccine viruses, W17D virus was subjected to ultrasonication for 1 min at 4 °C. The virus was then filtered using a 220 nm pore size membrane and the N test was repeated with this virus and MAb 612. The results were identical to those antisera against selected yellow fever mouse anti-YF W17D virus byperimmune presented above. Thus, vaccine and most wild-type viruses were readily distinguishable by their neutralization characteristics with MAb 612. Subsequently, N tests with W17D and MAb 864 were performed for comparison with the results already presented for MAb 612 and RH1. The neutralizing potency of MAb 864 far exceeded that of the other antibodies (1 × 106). Moreover, as was found with the SNI tests, there was no non-neutralizable virus fraction. It is relevant to note that with W17D virus the difference in antibody titre between MAb 864 and 612, when titrated by immunofluorescence, was less than tenfold but in N tests the difference in titre was more than 1 x 105. Thus, the significant differences in neutralizing potency were not due to differences in antibody concentration.
The results of N tests with plaque-purified vaccine and wild-type variants from Asibi, B5 and B12 virus are presented in Table 4 . For each virus the results obtained with one large-and one small-plaque variant are presented although in practice 18 different plaque variants were analysed. In general, plaque-purified viruses were neutralized more effectively than those not plaque-purified. Plaque-purified variants of B12 virus, however, retained the poor neutralization characteristics seen with the parent virus.
MAb 868, 813, 825 and 843 were then titrated in N tests with the 17D vaccines from different countries. The results confirmed those of the SNI tests, i.e. the U.K. vaccine (W17D) was neutralized more effectively than the other vaccines. For W17D the antibody neutralization titres were at least 1/32 whereas for the French, the South African, the Australian, the African, the German and the Dutch vaccines the titres were never higher than 1/16. This was also the case for the American vaccine except with MAb 825 which produced a titre of 1/24.
In the results presented, MAb 612 neutralized many wild-type YF isolates better than YF vaccine strains and the other monoclonal antibodies similarly produced poor neutralization In view of the observation that B 12 virus was not neutralized to any significant extent by most of the antibodies a hyperimmune mouse antiserum was prepared against this virus. SNI titrations were then performed with this antiserum using B12, B11, B5 and B7; these viruses were chosen because they showed differences in their abilities to be neutralized. As can be seen ( Table 5 ) the viruses that had been neutralized effectively in previous tests were also neutralized effectively with the mouse antiserum to B12, whereas B12 virus was neutralized much less effectively. Viruses W17D and FNV were included as controls for comparison.
Neutralization and passive protection in mice
In view of the large difference between the two viruses B12 and B7 in their ability to be neutralized by MAb 612 in vitro we decided to investigate whether or not MAb 612 could protect mice from intracerebral challenge with either B12 or B7 virus. Mouse protection by neutralization of virus infectivity and passive antibody transfer experiments were carried out as described in Methods. In contrast with the SNI and N tests, MAb 612 did not differentiate between the two viruses. There was no significant degree of protection in any of the experiments when compared with the negative and positive control groups.
SNI titrations with other flaviviruses
A selection of viruses representing each of the seven antigenic subgroups of the genus Flavivirus was used in SNI titrations with monoclonal and polyclonal antibodies known to react with the envelope glycoprotein of YF viruses. The results are presented in Table 6 . MAb 843 neutralized only two flaviviruses other than YF (Spondweni and dengue type 1) but 612 showed quite broad cross-reactivity as did the two polyclonal antisera. There was no correlation between the results obtained by immunofluorescence, reported previously (Gould et al., 1985) , and the neutralization results. The rabbit hyperimmune antiserum against WN virus (RH2) showed a broader degree of cross-reactivity in S N I than that against W 17D virus (RH 1). This is in spite of the fact that both antisera reacted with all flaviviruses when tested by immunofluorescence and that RH1 was superior to RH2 in its ability to neutralize YF virus strains. possible. Polyclonal antibodies (PAb) have been used extensively for taxonomic arrangements of flaviviruses (Porterfield, 1980) but it was inevitable that neutralization data with MAb would render this due for reassessment.
We have tested many MAb and PAb against a variety of vaccine and wild-type YF strains and against antigenically related flaviviruses. Major differences in neutralization susceptibilities have been detected despite the presence of relevant epitopes which could be demonstrated by immunofluorescence microscopy (Gould et al., 1985) . That these differences could have been due to mixed populations of antigenic variants seems unlikely since plaque-purified viruses retained the neutralization characteristics of their parents. The relative susceptibility of nonplaque-purified strains to neutralization was the same with several MAb; hence, the virus population was antigenically homogeneous. Furthermore, ELISA tests comparing the antibodybinding characteristics of many of these viruses did not show differences that could account for variations in neutralization (N. Cammack, personal communication).
Some monoclonal antibodies specific for the envelope glycoprotein did not neutralize any strains of YF virus and this was not influenced by the addition of anti-globulin, complement or even by combining MAb. Flamand et al. (1980) made a similar observation with strains of rabies virus. Therefore, neutralization of YF virus requires more than the mere presence of an epitope in the envelope spike glycoprotein. Since not all YF strains were neutralized by the same antibody, it seems that the location of the epitope on the spike is also critical. Our inability to effect neutralization using accessory factors emphasizes the importance of the 'critical site' on the virus as well as the 'critical area' referred to by Della-Porta & Westaway (1978) . Since some 17D vaccine and some wild-type YF virus strains tended to be neutralized by most antibodies whereas others did not, the accessibility of the entire neutralization site must be variable. Nevertheless, a poorly neutralized strain did induce the formation of heterologous neutralizing antibody. Thus, in neutralization reactions, the virus rather than the antibody is the determining factor.
Essentially, two categories of 17D vaccine were noted: those neutralized by more than three MAb and those neutralizable by fewer than three. Whether this can be related to the efficacy Of the vaccines in humans is not known. Liprandi (1981) showed that vaccines are heterogeneous and modernization of methods for vaccine production and standardization are clearly necessary (Woodall, 1981) . Our results may also explain inconsistencies in neutralization data obtained by others with vaccine and Asibi YF (Schlesinger et al., 1983) .
Particularly striking was the potency of MAb 864 against all 17D vaccines (Table 2 ). This may reflect the relative prominence of the corresponding epitope compared with other epitopes in the neutralizing domain of 17D. To some extent it is also confirmed by the greater neutralizing power of RH1 (anti-17D) than RH2 (anti-WN) against 17D strains. Against other flaviviruses (Table 5) RH2 was the stronger antiserum.
With MAb 612, wild-type and vaccine YF could be clearly distinguished using N tests ( Fig.  1 a, b) . Plaque purification did not make any difference, nor did ultrasonication and filtration of virus. With one or two exceptions, wild-type strains were more readily neutralized than vaccine strains. However, this difference did not appear with PAb RH1; this must reflect the relative dominance of particular epitopes in the three-dimensional structure of the neutralization zone (see Atassi, 1980) . For example, in vaccine strains, the epitope recognized by MAb 612 might be less favourably placed for neutralization than in some wild-type strains not possessing the epitope recognized by MAb 864. The PAb, however, must contain antibody molecules equivalent to MAb 864 and MAb 612 to ensure effective neutralization of either vaccine or wildtype viruses.
In some cases the neutralization index of MAb was very high; for example, MAb 864 totally neutralized all 17D virus infectivity (Table 2 ) whereas other MAbs with equally high titres by immunofluorescence had much lower neutralization indices. This seems to support the idea that the disposition of the epitope in the glycoprotein spike is more important for neutralization than the numbers of different antibody molecules that can attach at any one time, which is in contrast with the findings of Kingsford (1984) who studied neutralization of La Crosse virus.
We have not identified the mechanisms of YF virus neutralization but have shown that there are dominant and non-dominant zones in the neutralization site of the viral envelope. Since
